Barrett's esophagus in 2008: An update

Keio Journal of Medicine

Volumn 57, Issue 3, 2008, Pages 132-138

  Wood, Richard K ^a   Yang, Yu Xiao ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Barrett's; Barrett's surveillance; High grade dysplasia

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CHEMOPROPHYLAXIS; DISEASE COURSE; DISEASE SURVEILLANCE; DYSPLASIA; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC THERAPY; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; NONHUMAN; OBESITY; PHOTODYNAMIC THERAPY; PREVALENCE; REVIEW; RISK FACTOR; SEX DIFFERENCE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GASTROENTEROLOGY; HELICOBACTER INFECTIONS; HUMANS; MALE; OBESITY; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 56049085160     PISSN: 00229717     EISSN: 18801293     Source Type: Journal    
DOI: 10.2302/kjm.57.132     Document Type: Review

References (40)

1. El-Serag HB, Mason AC, Petersen N, Key CR: Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002; 50: 368-372
2. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB: Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the united states: A glimmer of hope? American Journal of Gastroenterology 2003; 98: 1627-1633
3. Piazuelo MB, Haque S, Delgado, Alberto: Du, Joanna X., Rodriguez F, Correa P: Phenotypic differences between gastric and esophageal intestinal metaplasia. Modern Pathology 2004; 17: 62-74
4. Sharma P, Dent J, Armstrong D, Bergman JJGHM, Gossner L, Hoshihara Y, et al.: The development and validation of an endoscopic grading system for barrett's esophagus: The prague C & M criteria. Gastroenterology 2006; 131: 1392-1399
5. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RKH, Vasudeva RS, et al.: Screening for barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-1677
6. Ronkainen J, Aro P, Storskrubb T, Johansson S, Lind T, Bolling-Sternevald E, et al.: Prevalence of barrett's esophagus in the general population: An endoscopic study. Gastroenterology 2005; 129: 1825-1831
7. Hongo M: Review article: Barrett's oesophagus and carcinoma in japan. Alimentary Pharmacology & Therapeutics 2004; 20 Suppl 8: 50-54
8. Sharma P, McQuaid K, Dent J, Fennerty MB, Sampliner R, Spechler S, et al.: A critical review of the diagnosis and management of barrett's esophagus: The AGA chicago workshop. Gastroenterology 2004; 127: 310-330
9. Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology: Updated guidelines for the diagnosis, surveillance, and therapy of barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-1895
10. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N: Screening and surveillance for barrett esophagus in high-risk groups: A cost-utility analysis. Ann Intern Med 2003; 138: 176-186
11. Gerson LB, Groeneveld PW, Triadafilopoulos G: Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2004; 2: 868-879
12. Lin OS, Schembre DB, Mergener K, Spaulding W, Lomah N, Ayub K, et al.: Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of barrett's esophagus in patients with chronic gastroesophageal reflux. Gastrointestinal Endoscopy 2007; 65: 577-583
13. Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of barrett's esophagus. Clin Gastroenterol Hepatol 2007; 5: 319-325
14. Rubenstein JH, Inadomi JM, Brill JV, Eisen GM: Cost utility of screening for barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol 2007; 5: 312-318
15. Lieberman DA, Oehlke M, Helfand M: Risk factors for barrett's esophagus in community-based practice. GORGE consortium. gastroenterology outcomes research group in endoscopy. Am J Gastroenterol 1997; 92: 1293-1297
16. Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
17. Gerson LB, Shetler K, Triadafilopoulos G: Prevalence of barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-467
18. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM: Preoperative prevalence of barrett's esophagus in esophageal adenocarcinoma: A systematic review. Gastroenterology 2002; 122: 26-33
19. Lagergren J, Bergstrom R, Nyren O: Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883-890
20. El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR: Abdominal obesity and the risk of barrett's esophagus. American Journal of Gastroenterology 2005; 100: 2151-216
21. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, et al.: Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007; 133: 34-41
22. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL: Central adiposity and risk of barrett's esophagus. Gastroenterology 2007; 133: 403-411
23. Lagergren J, Nyren O: Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1998; 7: 913-915
24. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, et al.: Helicobacter pylori infection and gastric atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. Journal of the National Cancer Institute 2004; 96: 388-396
25. Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarcinoma in columnar-lined (barrett's) esophagus. N Engl J Med 1985; 313: 857-859
26. Reid BJ, Weinstein WM: Barrett's esophagus and adenocarcinoma. Annu Rev Med 1987; 38: 477-492
27. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS: Is there publication bias in the reporting of cancer risk in barrett's esophagus? Gastroenterology 2000; 119: 333-338
28. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ: Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (barrett's) tissue. J Natl Cancer Inst 1999; 91: 2087-2095
29. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, et al.: p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in barrett's metaplastic epithelium. Cancer Res 2001; 61: 8284-8289
30. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al.: Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006; 38: 468-473
31. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58: 2929-2934
32. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ: Predictors of progression in barrett's esophagus III: Baseline flow cytometric variables. Am J Gastroenterol 2001; 96: 3071-3083
33. Fitzgerald RC, Omary MB, Triadafilopoulos G: Dynamic effects of acid on barrett's esophagus. an ex vivo proliferation and differentiation model. Journal of Clinical Investigation 1996; 98: 2120-2028
34. Katzka DA, Castell DO: Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with barrett's esophagus. Am J Gastroenterol 1994; 89: 989-991
35. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high-grade dysplasia in barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120: 1630-1639
36. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, et al.: Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357: 360-369
37. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS: Predictors of progression to cancer in barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000; 95: 1669-1676
38. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al.: Long-term nonsurgical management of barrett's esophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-1619
39. Pellegrini CA, Pohl D: High-grade dysplasia in barrett's esophagus: Surveillance or operation? J Gastrointest Surg 2000; 4: 131-134
40. Prasad GA, Wang KK, Buttar NS, Wongkeesong L, Krishnadath KK, Nichols FC,3rd, et al.: Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in barrett's esophagus. Gastroenterology 2007; 132: 1226-1233